{"entity":{"id":"nct05221840","kind":"trial","name":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","aka":["PACIFIC-9"],"tldr":"A phase 3 trial testing Oleclumab in non-small-cell lung cancer, active and no longer recruiting.","summary":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05221840, led by AstraZeneca, and active but no longer recruiting on the registry. Official title: A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy. Planned enrolment is 1051 participants (actual). The study started in 2022-02-07 and primary completion is expected in 2026-09-30. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05221840","url":"https://clinicaltrials.gov/study/NCT05221840"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","stage-iii-unresectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["oleclumab","monalizumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05221840","phase":"3","setting":"A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy","sponsor":"AstraZeneca","started":"2022-02-07","startedType":"actual","enrolled":1051,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05221840/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"drug":[{"id":"monalizumab","kind":"drug","name":"Monalizumab","route":"/drugs/monalizumab/"},{"id":"oleclumab","kind":"drug","name":"Oleclumab","route":"/drugs/oleclumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}